Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid

Journal of Pharmaceutical and Biomedical Analysis

Volumn 96, Issue , 2014, Pages 10-20

  Yuvaraja, K ^a   Khanam, Jasmina ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Carvedilol; Cyclodextrin; Dissolution enhancement; Ionization process; Tartaric acid; Water soluble polymer

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; CARVEDILOL; CYCLODEXTRIN DERIVATIVE; DRUG CARRIER; HYDROXYL GROUP; POLOXAMER; POLYMER; POLYVINYL PYRROLIDONE K 30; POVIDONE; TARTARIC ACID; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CYCLODEXTRIN; EXCIPIENT; PROPANOLAMINE DERIVATIVE; TARTARIC ACID DERIVATIVE; WATER;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIELECTRIC CONSTANT; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BINDING; DRUG SOLUBILITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTITION COEFFICIENT; PH; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID DISPERSION TECHNIQUE; SOLID STATE; X RAY DIFFRACTION; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; MEDICINAL CHEMISTRY; SOLUBILITY;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CYCLODEXTRINS; DRUG CARRIERS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; POLYMERS; PROPANOLAMINES; SOLUBILITY; TARTRATES; WATER;

EID: 84897500534     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.03.019     Document Type: Article

References (49)

1. Friesen D.T., Crew M., Curatolo W.J., Nightingale J.A.S., Ravi Shanker, Smithey D.T. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm. 2008, 5:1003-1019.
2. Pouton C.W., Benameur H., Porter C.J.H., Warren D.B. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J. Drug Target. 2010, 18:704-731.
3. Wu C., Williams R.O., Donnell K.O., Dong Y., Lang B., Li H., Zhang H., Zhang M., Wang Z. Formulation and delivery of improved amorphous fenofibrate solid dispersion prepared by thin film freezing. Eur. J. Pharm. Biopharm. 2012, 82:534-544.
4. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 10:1058-1066.
5. Das S.K., Nanda A., Khanam J., Yuvaraja K., Roy S. Solid dispersions: an approach to enhance the bioavailability of poorly water soluble drugs. IJPPT 2012, 1:37-46.
6. Maulvi F.A., Dalwadi S.J., Gandhi T.R., Gohel M.C., Soni T.G., Thakkar V.T. Improvement of dissolution rate of aceclofenac by solid dispersion technique. Powder Technol. 2011, 207:47-54.
7. Feuerstein G., Arch J.R.S., Cheng H.Y., Lin Liu G., Li Yue T., Ma X.L., Paul Hieble J., Ruffolo R.R. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur. J. Pharmacol. 1998, 351:341-350.
8. Palazzuoli A., Auteri A., Calabria P., Verzuri M.S. Carvedilol: something else than a simple betablocker?. Eur. Rev. Med. Pharmacol. Sci. 2002, 6:115-126.
9. Khang G., Cho W.H., Lee D., Lee E.Y., Lim D.K., Oh M.J., Shim J.B., Yoo H. Molecular effect of PVP on the release property of carvedilol solid dispersion. J. Pharm. Investig. 2011, 41:179-184.
10. Wen X., Jing Z., Liu Z., Tan F. Preparation and study the 1:2 inclusion complex of carvedilol with β-cyclodextrin. J. Pharm. Biomed. Anal. 2004, 34:517-523.
11. Bandari S., Jukanti R., Potluri R.H.K., Veerareddy P.R. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with gelucire 50/13. Arch. Pharm. Res. 2011, 34:51-57.
12. Pokharkar V., Dhar S., Khanna A., Mandpe L., Venkatpurwar V. Ternary complexation of carvedilol, β-cyclodextrin and citric acid for mouth-dissolving tablet formulation. Acta Pharm. 2009, 59:121-132.
13. Hirlekar R., Kadam V. Preparation and characterization of inclusion complexes of carvedilol with methyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 2009, 63:219-224.
14. Planinsek O., Kovacic B., Vrecer F. Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. Int. J. Pharm. 2011, 406:41-48.
15. Tapas A., Kawtikwar P., Sakarkar D. An improvement in physicochemical properties of carvedilol through spherically agglomerated solid dispersions with PVP K30. Acta Pol. Pharm. 2012, 69:299-308.
16. Hiremath S.N., Bhautani S., Raju S.A., Swamy P.V. Preparation and evaluation of inclusion complexes of carvedilol. J. Sci. Ind. Res. 2007, 66:830-834.
17. Loftsson T., Desbos C., Jansook P., Vogensen S.B. Carvedilol: solubilisation and cyclodextrin complexation: a technical note. AAPs PharmSciTech 2008, 9:425-430.
18. Singh S., Chakraborty S., Jain A., Mishra B., Shukla D. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J. Colloid Interface Sci. 2009, 335:242-249.
19. Reddy B.S.R., Bakrudeen H.B., Kannan A.S., Lakshmi M.S., Mandal A.B., Sriranjani M. Carvedilol/montmorillonite: processing, characterization and release studies. Appl. Clay Sci. 2010, 48:589-593.
20. Fathy M., Badry M.E. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone k-30. Drug Dev. Ind. Pharm. 2006, 32:141-150.
21. Dumortier G., Agnely F., Chaumeil J.C., Grossiors J.L. A review of Poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 2006, 23:2709-2728.
22. Veiga F.J.B., Carvalho R.A., Ferrerira D.C., Ribeiro L. Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies. Eur. J. Pharm. Sci. 2005, 24:1-13.
23. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
24. OECD Guidelines for the Testing of Chemicals, 1995, p. 107.
25. A.H. Beckett, J.B. Stenlake, Electro chemical methods, in: G.O. Jolliffe (Ed.), Practical Pharmaceutical Chemistry, vol. 2, London, 1988, pp. 183-208.
26. Higuchi T., Connor's K.A. Phase-solubility techniques. Advances in Analytical Chemistry and Instrumentation 1965, vol. 4:117-212. Interscience, New York.
27. Paradkar A., Ambike A.A., Mahadik K.R., Mandpe L.P., Padamwar M.N., Pokharkar V.B. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol. 2006, 167:20-25.
28. Sharma A., Jain C.P. Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res. Pharm. Sci. 2010, 5:49-56.
29. Loftsson T., Masson M., Schipper N., Sigurdsson1 H.H. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie 2004, 59:25-29.
30. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
31. Sinko P.J., Singh Y. Martin's Physical Pharmacy and Pharmaceutical Sciences 2006, 54-77. Lippincott Williams & Wilkins, Baltimore. sixth ed.
32. Fenyvesi E., Delcanale M., Redenti E., Szejtli J., Szeman J., Ventura P., Vikmon M. Interaction of hydroxy-acids with β-cyclodextrin. J. Incl. Phenom. Macroc. Chem. 1999, 33:339-344.
33. Mura P., Bramanti G., Faucci M.T., Manderioli A. Multicomponent systems of econazole with hydroxyacids and cyclodextrins. J. Incl. Phenom. Macroc. Chem. 2001, 39:131-138.
34. Redenti E., Szejtli J., Szente L. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci. 2000, 89:1-8.
35. Domanska U., Pelczarska A., Pobudkowska A. Effect of 2-hydroxypropyl-β-cyclodextrin on solubility of sparingly soluble drug derivatives of anthranilic acid. Int. J. Mol. Sci. 2011, 12:2383-2394.
36. Veiga F.J.B., Fernandes C.M., Vieira M.T. Physiochemical characterization and in vitro dissolution behaviour of nicardipine-cyclodextrins inclusion compounds. Eur. J. Pharm. Sci. 2002, 15:79-88.
37. Marques H. Application of cyclodextrins. Thermodynamic aspects of cyclodextrin complexes. Rev. Port. Farm. 1994, 44:85-96.
38. Paradkar A., Ambike A.A., Jadhav K.B., Mahadik K.R. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm. 2004, 271:281-286.
39. Wang J., Cao Y., Sun B., Wang C. Characterisation of inclusion complex of trans-ferulic acid and hydroxypropyl-β-cyclodextrin. Food Chem. 2011, 124:1069-1075.
40. Li W., Lan Z., Li B., Li M., Sun L., Tan L., Yang X., Yu M. Investigation of structure and dissolution properties of a solid dispersion of lansoprazole in polyvinylpyrrolidone. J. Mol. Struct. 2011, 1005:70-77.
41. Pincu E., Meltzer V. Thermodynamic study of binary mixture of citric acid and tartaric acid. Cent. Eur. J. Chem. 2012, 10:1584-1589.
42. ®: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol. 2013, 237:406-414.
43. Guyot M., Lagueny A.M., Bonini F., Fawaz F., Bildet J. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions. Int. J. Pharm. 1995, 123:53-63.
44. Veiga F.J.B., Figueiras A., Labandeira J.J.T., Ribeiro L., Carvalho R.A. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. Eur. J. Pharm. Biopharm. 2007, 67:531-539.
45. Labandeira J.J.T., Jato J.L.V., Lopez M.E., Seijo L.C., Penin L.S. Complexation of the interferon inducer, bropirimine, with hydroxypropyl-β-cyclodextrin. Eur. J. Pharm. Sci. 2000, 9:381-386.
46. Dollo G., Chevanne F., Le Verge R., Le Corre P. Inclusion complexation of amide-typed local anaesthetics with g-cyclodextrin and its derivatives. I. Physicochemical characterization. Int. J. Pharm. 1996, 131:219-228.
47. Bhosale P., Sayyad F., Pore Y. Preparation of amorphous carvedilol polymeric microparticles for improvement of physicochemical properties. Int. J. Pharm. Investig. 2012, 42:335-344.
48. Forni F., Mucci A., Salvioli G., Vandelli M.A., Malmusi L., Panini R. 2-Hydroxypropyl-β-cyclodextrin complexation with ursodeoxycholic acid. Int. J. Pharm. 1995, 118:77-83.
49. Veiga F., Dias J.J.C.T., Kedzierewicz F., Sousa A., Maincet P. Inclusion complexation of tolbutamide with βcyclodextrin and hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 1996, 129:63-71.